While the EMA says ‘possible link’ found between jab and ‘unusual’ blood clots, UK offers young people alternative shot due to risks.
The embattled AstraZeneca vaccine came under further pressure on Wednesday, as the European Union’s medicines regulator found a possible link between the shot and rare cases of blood clots, while the UK announced it would offer young people an alternative jab due to the risks.
The European Medicines Agency (EMA)’s widely anticipated verdict on Wednesday followed a review dozens of reports of an extremely rare clot in the brain, known as cerebral venous sinus thrombosis (CVST).
It also concluded that unusual blood clots with low blood platelets should be listed as very rare side effects of the jab.
“EMA is reminding healthcare professionals and people receiving the vaccine to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within two weeks of vaccination,” the body said in a statement.
“So far, most of the cases reported have occurred in women under 60 years of age within two weeks of vaccination. Based on the currently available evidence, specific risk factors have not been confirmed.”
In a separate development, the UK said people aged between 18 and 29 would be offered an alternative vaccine to AstraZeneca given the risk of blood clots.
This is breaking news story. More details to follow.